Clinical
Trials
Finder
Conditions
Locations
Institutions
Search Trials
Search
Conditions
Locations
Institutions
Search Trials
Institutions
Harbour Cancer & Wellness ( Site 5600)
Harbour Cancer & Wellness ( Site 5600)
Newmarket, Auckland, New Zealand
1 recruiting
Showing
1–1
of
1
trials
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
1,000 enrolled
250 locations
NCT06841354
Feedback